CYP3A4-mediated pharmacokinetic interactions in cancer therapy

Current Drug Metabolism

Volumn 15, Issue 8, 2014, Pages 808-817

  Tian, Dandan ^a   Hu, Zheyi ^b  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Anticancer drugs; Cytochromes P450 (CYP) enzymes; Drug drug interactions; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 ISOENZYME; ECHINACEA EXTRACT; GARLIC EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; KAVA; PRESCRIPTION DRUG; SILYBUM MARIANUM EXTRACT; ANTINEOPLASTIC AGENT; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450; CYTOCHROME P450 3A;

ACTAEA RACEMOSA; AREA UNDER THE CURVE; ARTICLE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; HERB DRUG INTERACTION; HUMAN; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; DRUG EFFECTS; DRUG INTERACTION; METABOLISM; NEOPLASMS;

ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; NEOPLASMS;

EID: 84928395247     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200216666150223152627     Document Type: Article

References (77)

1. Jorgensen, T.; Johansson, S.; Kennerfalk, A.; Wallander, M.A.; Svardsudd, K. Prescription drug use, diagnoses, and healthcare utilization among the elderly. Ann. Pharmacother., 2001, 35(9), 1004-9.
2. Blower, P.; de Wit, R.; Goodin, S.; Aapro, M. Drug-drug interactions in oncology: why are they important and can they be minimized? Crit. Rev. Oncol. Hematol., 2005, 55(2), 117-42.
3. Scripture, C.D.; Figg, W.D. Drug interactions in cancer therapy. Nat. Rev. Cancer, 2006, 6(7), 546-58.
4. Venkatakrishnan, K.; von Moltke, L.L.; Greenblatt, D.J. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin. Pharmacokinet., 2000, 38(2), 111-80.
5. Gibbs, M.A.; Thummel, K.E.; Shen, D.D.; Kunze, K.L. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab. Dispos., 1999, 27(2), 180-7.
6. Chien, J.Y.; Lucksiri, A.; Ernest, C.S. 2nd; Gorski, J.C.; Wrighton, S.A.; Hall, S.D. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole. Drug Metab. Dispos., 2006, 34(7), 1208-19.
7. Chen, M.; Nafziger, A.N.; Bertino J.S. Jr. Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam. Drug Metab. Dispos., 2006, 34(12), 2079-82.
8. U. S. Food and Drug Administration/Center for Drug Evaluation and Research, Guidance for Industry: Drug Interactions Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. FDA: Silver Spring, 2012; (http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064982.htm) (Accessed August 15, 2014).
9. Di, Y.M.; Li, C.G.; Xue, C.C.; Zhou, S.F. Clinical drugs that interact with St. John's wort and implication in drug development.Curr. Pharm. Des., 2008, 14(17), 1723-42.
10. Venkatakrishnan, K.; Rader, M.; Ramanathan, R.K.; Ramalingam, S.; Chen, E.; Riordan, W.; Trepicchio, W.; Cooper, M.; Karol, M.; von Moltke, L.; Neuwirth, R.; Egorin, M.; Chatta, G. Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: A prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study. Clin. Ther., 2009, 31 Pt 2, 2444-58.
11. Abbas, R.; Hug, B.A.; Leister, C.; Burns, J.; Sonnichsen, D. Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects. J. Clin. Pharmacol., 2011, 51(12), 1721-7.
12. ClinicalTrials.gov, Estimation of effect of ketoconazole on pharmacokinetics of crizotinib in healthy volunteers-Study Results; (http://clinicaltrials.gov/ct2/show/results/NCT01149785?sect=X01256#all) (Accessed August 15, 2014).
13. ClinicalTrials.gov, Estimation of effect of rifampin on pharmacokinetics of crizotinib in healthy volunteers-Study Results; (http://clinicaltrials.gov/ct2/show/results/NCT01147055?sect=X87i0156#outcome2) (Accessed August 15, 2014).
14. Huang, Z.; Roy, P.; Waxman, D.J. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem. Pharmacol., 2000, 59(8), 961-72.
15. de Jonge, M.E.; Huitema, A.D.; van Dam, S.M.; Beijnen, J.H.; Rodenhuis, S. Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin. Cancer Chemother. Pharmacol., 2005, 55(5), 507-10.
16. Kerbusch, T.; Jansen, R.L.; Mathot, R.A.; Huitema, A.D.; Jansen, M.; van Rijswijk, R.E.; Beijnen, J.H. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin. Clin. Pharmacol. Ther., 2001, 70(2), 132-41.
17. Kamath, A.V.; Wang, J.; Lee, F.Y.; Marathe, P.H. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): A potent oral multi-targeted kinase inhibitor against SRC and BCRABL. Cancer Chemother. Pharmacol.,2008, 61(3), 365-76.
18. Johnson, F.M.; Agrawal, S.; Burris, H.; Rosen, L.; Dhillon, N.; Hong, D.; Blackwood-Chirchir, A.; Luo, F.R.; Sy, O.; Kaul, S.; Chiappori, A.A. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer, 2010, 116(6), 1582-91.
19. Shou, M.; Martinet, M.; Korzekwa, K.R.; Krausz, K.W.; Gonzalez, F.J.; Gelboin, H.V. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics, 1998, 8(5), 391-401.
20. Engels, F.K.; Ten Tije, A.J.; Baker, S.D.; Lee, C.K.; Loos, W.J.; Vulto, A.G.; Verweij, J.; Sparreboom, A. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin. Pharmacol. Ther., 2004, 75(5), 448-54.
21. Van Veldhuizen, P.J.; Reed, G.; Aggarwal, A.; Baranda, J.; Zulfiqar, M.; Williamson, S. Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma: A phase I and pharmacokinetic study. Cancer, 2003, 98(9), 1855-62.
22. Figg, W.D.; Woo, S.; Zhu, W.; Chen, X.; Ajiboye, A.S.; Steinberg, S.M.; Price, D.K.; Wright, J.J.; Parnes, H.L.; Arlen, P.M.; Gulley, J.L.; Dahut, W.L. A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. J. Urol., 2010, 183(6), 2219-26.
23. Rakhit, A.; Pantze, M.P.; Fettner, S.; Jones, H.M.; Charoin, J.E.; Riek, M.; Lum, B.L.; Hamilton, M. The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (Sim-CYP) predicts in vivo metabolic inhibition. Eur. J. Clin. Pharmacol., 2008, 64(1), 31-41.
24. TARCEVA® (erlotinib) tablets, for oral use. Initial U.S. Approval: 2004; (http://www.gene.com/download/pdf/tarceva-prescribing.pdf) (Accessed August 15, 2014).
25. Kuhn, B.; Jacobsen, W.; Christians, U.; Benet, L.Z.; Kollman, P.A. Metabolism of sirolimus and its derivative everolimus by cytochrome P450 3A4: insights from docking, molecular dynamics, and quantum chemical calculations. J. Med. Chem., 2001, 44(12), 2027-34.
26. Kovarik, J.M.; Beyer, D.; Bizot, M.N.; Jiang, Q.; Shenouda, M.; Schmouder, R.L. Blood concentrations of everolimus are markedly increased by ketoconazole. J. Clin. pharmacol., 2005, 45(5), 514-8.
27. Kovarik, J.M.; Hartmann, S.; Figueiredo, J.; Rouilly, M.; Port, A.; Rordorf, C. Effect of rifampin on apparent clearance of everolimus. Ann. Pharmacother., 2002, 36(6), 981-5.
28. Swaisland, H.C.; Ranson, M.; Smith, R.P.; Leadbetter, J.; Laight, A.; McKillop, D.; Wild, M.J. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin. Pharmacokinet., 2005, 44(10), 1067-81.
29. Padda, S.K.; Chhatwani, L.; Zhou, L.; Jacobs, C.D.; Lopez-Anaya, A.; Wakelee, H.A. Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-smallcell lung cancer: brief report. Anticancer Drugs, 2013, 24(7), 731-5.
30. Dutreix, C.; Peng, B.; Mehring, G.; Hayes, M.; Capdeville, R.; Pokorny, R.; Seiberling, M. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects.Cancer Chemother. Pharmacol., 2004, 54(4), 290-4.
31. Druker, B.J.; Talpaz, M.; Resta, D.J.; Peng, B.; Buchdunger, E.; Ford, J.M.; Lydon, N.B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S.; Sawyers, C.L. Efficacy and safety of a specific inhibitor of the BCRABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 2001, 344(14), 1031-7.
32. van Erp, N.P.; Gelderblom, H.; Karlsson, M.O.; Li, J.; Zhao, M.; Ouwerkerk, J.; Nortier, J.W.; Guchelaar, H.J.; Baker, S.D.; Sparreboom, A. Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib.Clin. Cancer Res., 2007, 13(24), 7394-400.
33. Cohen, M.H.; Williams, G.; Johnson, J.R.; Duan, J.; Gobburu, J.; Rahman, A.; Benson, K.; Leighton, J.; Kim, S.K.; Wood, R.; Rothmann, M.; Chen, G.; U, K.M.; Staten, A.M.; Pazdur, R. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res., 2002, 8(5), 935-42.
34. Bolton, A.E.; Peng, B.; Hubert, M.; Krebs-Brown, A.; Capdeville, R.; Keller, U.; Seiberling, M. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother. Pharmacol., 2004, 53(2), 102-6.
35. Smith, P.; Bullock, J.M.; Booker, B.M.; Haas, C.E.; Berenson, C.S.; Jusko, W.J. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy, 2004, 24(11), 1508-14.
36. Santos, A.; Zanetta, S.; Cresteil, T.; Deroussent, A.; Pein, F.; Raymond, E.; Vernillet, L.; Risse, M.L.; Boige, V.; Gouyette, A.; Vassal, G. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin. Cancer Res., 2000, 6(5), 2012-20.
37. Kehrer, D.F.; Mathijssen, R.H.; Verweij, J.; de Bruijn, P.; Sparreboom, A. Modulation of irinotecan metabolism by ketoconazole. J. Clin. Oncol., 2002, 20(14), 3122-9.
38. Murry, D.J.; Cherrick, I.; Salama, V.; Berg, S.; Bernstein, M.; Kuttesch, N.; Blaney, S.M. Influence of phenytoin on the disposition of irinotecan: A case report. J. Pediatr. Hematol. Oncol., 2002, 24(2), 130-3.
39. Mathijssen, R.H.; Verweij, J.; de Bruijn, P.; Loos, W.J.; Sparreboom, A. Effects of St. John's wort on irinotecan metabolism. J. Natl. Cancer Inst., 2002, 94(16), 1247-9.
40. Smith, D.A.; Koch, K.M.; Arya, N.; Bowen, C.J.; Herendeen, J.M.; Beelen, A. Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects. Br. J. Clin. Pharmacol., 2009, 67(4), 421-6.
41. Dutreix, C.; Munarini, F.; Lorenzo, S.; Roesel, J.; Wang, Y. Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers. Cancer Chemother. Pharmacol., 2013, 72(6), 1223-34.
42. Lorusso, P.; Heath, E.I.; McGreivy, J.; Sun, Y.N.; Melara, R.; Yan, L.; Malburg, L.; Ingram, M.; Wiezorek, J.; Chen, L.; Pilat, M.J. Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors. Invest. New Drugs, 2008, 26(5), 455-62.
43. Abbas, R.; Hug, B.A.; Leister, C.; Burns, J.; Sonnichsen, D. Pharmacokinetics of oral neratinib during co- Administration of ketoconazole in healthy subjects. Br. J. Clin. Pharmacol., 2011, 71(4), 522-7.
44. Tanaka, C.; Yin, O.Q.; Smith, T.; Sethuraman, V.; Grouss, K.; Galitz, L.; Harrell, R.; Schran, H. Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants. J. Clin. Pharmacol., 2011, 51(1), 75-83.
45. Mounier, N.; Katlama, C.; Costagliola, D.; Chichmanian, R.M.; Spano, J.P. Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice. Crit. Rev. Oncol. Hematol., 2009, 72(1), 10-20.
46. Freimuth, W.W. Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Adv. Exp. Med. Biol., 1996, 394, 279-89.
47. Secord, A.A.; Teoh, D.K.; Barry, W.T.; Yu, M.; Broadwater, G.; Havrilesky, L.J.; Lee, P.S.; Berchuck, A.; Lancaster, J.; Wenham, R.M. A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer. Clin. Cancer Res., 2012, 18(19), 5489-98.
48. Shi, J.G.; Chen, X.; Emm, T.; Scherle, P.A.; McGee, R.F.; Lo, Y.; Landman, R.R.; G., M.E.,Jr; Punwani, N.G.; Williams, W.V.; Yeleswaram, S. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. J. Clin. Pharmacol., 2012, 52(6), 809-18.
49. Keating, G.M.; Santoro, A. Sorafenib: A review of its use in advanced hepatocellular carcinoma. Drugs, 2009, 69(2), 223-40.
50. Lathia, C.; Lettieri, J.; Cihon, F.; Gallentine, M.; Radtke, M.; Sundaresan, P. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother. Pharmacol., 2006, 57(5), 685-92.
51. Strumberg, D.; Richly, H.; Hilger, R.A.; Schleucher, N.; Korfee, S.; Tewes, M.; Faghih, M.; Brendel, E.; Voliotis, D.; Haase, C.G.; Schwartz, B.; Awada, A.; Voigtmann, R.; Scheulen, M.E.; Seeber, S. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol., 2005, 23(5), 965-72.
52. Sakamoto, K.M. Su-11248 Sugen. Curr. Opin. Investig. Drugs, 2004, 5(12), 1329-39.
53. Houk, B.E.; Bello, C.L.; Kang, D.; Amantea, M. A population pharmacokinetic meta- Analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin. Cancer Res., 2009, 15(7), 2497-506.
54. Washington, C.; Eli, M.; Bello, C.; Schaaf, L.; Polasek, E.; Tan, L.H., Scigalla, P.; Sarapa, N. The effect of ketoconazole (KETO), a potent CYP3A4 inhibitor, on SU011248 pharmacokinetics (PK) in Caucasian and Asian healthy subjects. Proc. Am. Soc. Clin. Oncol., 2003, 22(138), abstract 553.
55. Bello, C.; Houk, B.; Sherman, L.; Misbah, S.; Sarapa, N.; Smeraglia, J.; Haung, X. Effect of rifampin on the pharmacokinetics of SU11248 in healthy volunteers. J. Clin. Oncol., 2005, 23(suppl-16S), abstract 3078.
56. Villikka, K.; Kivisto, K.T.; Maenpaa, H.; Joensuu, H.; Neuvonen, P.J. Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin. Pharmacol. Ther., 1999, 66(6), 589-93.
57. Bjornsson, T.D.; Callaghan, J.T.; Einolf, H.J.; Fischer, V.; Gan, L.; Grimm, S.; Kao, J.; King, S.P.; Miwa, G.; Ni, L.; Kumar, G.; McLeod, J.; Obach, R.S.; Roberts, S.; Roe, A.; Shah, A.; Snikeris, F.; Sullivan, J.T.; Tweedie, D.; Vega, J.M.; Walsh, J.; Wrighton, S.A.; Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/Clinical Pharmacology Technical Working Group; FDA Center for Drug Evaluation and Research (CDER). Drug Metab. Dispos., 2003, 31(7), 815-32.
58. Mao, J.; Johnson, T.R.; Shen, Z.; Yamazaki, S. Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes. Drug Metab. Dispos., 2013, 41(2), 343-52.
59. Flaherty, K.T.; Lathia, C.; Frye, R.F.; Schuchter, L.; Redlinger, M.; Rosen, M.; O'Dwyer, P.J. Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: A phase I/II pharmacokinetic interaction study. Cancer Chemother. Pharmacol., 2011, 68(5), 1111-8.
60. Wang, Z.X.; Sun, J.; Howell, C.E.; Zhou, Q.Y.; He, Z.X.; Yang, T.; Chew, H.; Duan, W.; Zhou, Z.W.; Kanwar, J.R.; Zhou, S.F. Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies. Fundam. Clin. Pharmacol., 2014, 28(5), 551-82.
61. O'Brien, S.G.; Meinhardt, P.; Bond, E.; Beck, J.; Peng, B.; Dutreix, C.; Mehring, G.; Milosavljev, S.; Huber, C.; Capdeville, R.; Fischer, T. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia.Br. J. Cancer, 2003, 89(10), 1855-9.
62. Filppula, A.M.; Laitila, J.; Neuvonen, P.J.; Backman, J.T. Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br. J. Pharmacol.,2012, 165(8), 2787-98.
63. Goh, B.C.; Reddy, N.J.; Dandamudi, U.B.; Laubscher, K.H.; Peckham, T.; Hodge, J.P.; Suttle, A.B.; Arumugham, T.; Xu, Y.; Xu, C.F.; Lager, J.; Dar, M.M.; Lewis, L.D. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors. Clin. Pharmacol. Ther., 2010, 88(5), 652-9.
64. Burris, H.A.,3rd; Dowlati, A.; Moss, R.A.; Infante, J.R.; Jones, S.F.; Spigel, D.R.; Levinson, K.T.; Lindquist, D.; Gainer, S.D.; Dar, M.M.; Suttle, A.B.; Ball, H.A.; Tan, A.R. Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors. Mol. Cancer Ther., 2012, 11(8), 1820-8.
65. Jaremko, M.; Kasai, Y.; Barginear, M.F.; Raptis, G.; Desnick, R.J.; Yu, C. Tamoxifen metabolite isomer separation and quantification by liquid chromatography-tandem mass spectrometry. Anal. Chem., 2010, 82(24), 10186-93.
66. Dowsett, M.; Pfister, C.; Johnston, S.R.; Miles, D.W.; Houston, S.J.; Verbeek, J.A.; Gundacker, H.; Sioufi, A.; Smith, I.E. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clin. Cancer Res., 1999, 5(9), 2338-43.
67. Kamdem, L.K.; Liu, Y.; Stearns, V.; Kadlubar, S.A.; Ramirez, J.; Jeter, S.; Shahverdi, K.; Ward, B.A.; Ogburn, E.; Ratain, M.J.; Flockhart, D.A.; Desta, Z. In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br. J. Clin. Pharmacol., 2010, 70(6), 854-69.
68. Grimm, S.W.; Dyroff, M.C. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase. Drug Metab. Dispos., 1997, 25(5), 598-602.
69. Dowsett, M.; Tobias, J.S.; Howell, A.; Blackman, G.M.; Welch, H.; King, N.; Ponzone, R.; von Euler, M.; Baum, M. The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer. Br. J. cancer, 1999, 79(2), 311-5.
70. Dowsett, M.; Cuzick, J.; Howell, A.; Jackson, I.; Group, A.T. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: A sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial. Br. J. Cancer, 2001, 85(3), 317-24.
71. Riechelmann, R.P.; Tannock, I.F.; Wang, L.; Saad, E.D.; Taback, N.A.; Krzyzanowska, M.K. Potential drug interactions and duplicate prescriptions among cancer patients. J. Natl. Cancer Inst., 2007, 99(8), 592-600.
72. van Leeuwen, R.W.; Brundel, D.H.; Neef, C.; van Gelder, T.; Mathijssen, R.H.; Burger, D.M.; Jansman, F.G. Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br. J. Cancer, 2013, 108(5), 1071-8.
73. Kolesar, J.M.; Johnson, C.L.; Freeberg, B.L.; Berlin, J.D.; Schiller, J.H. Warfarin-5-FU interaction- A consecutive case series. Pharmacotherapy, 1999, 19(12), 1445-9.
74. LoRusso, P.M.; Jones, S.F.; Koch, K.M.; Arya, N.; Fleming, R.A.; Loftiss, J.; Pandite, L.; Gadgeel, S.; Weber, B.L.; Burris, H.A.3rd. Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer. J. Clin. Oncol., 2008, 26(18), 3051-6.
75. Chu, Q.S.; Cianfrocca, M.E.; Goldstein, L.J.; Gale, M.; Murray, N.; Loftiss, J.; Arya, N.; Koch, K.M.; Pandite, L.; Fleming, R.A.; Paul, E.; Rowinsky, E.K. A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer. Clin. Cancer Res., 2008, 14(14), 4484-90.
76. Simonelli, M.; Zucali, P.A.; Lorenzi, E.; Rubino, L.; De Vincenzo, F.; De Sanctis, R.; Perrino, M.; Mancini, L.; Di Tommaso, L.; Rimassa, L.; Masci, G.; Zuradelli, M.; Suter, M.B.; Bertossi, M.; Fattuzzo, G.; Giordano, L.; Roncalli, M.G.; Santoro, A. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors. Eur. J. Cancer, 2013, 49(5), 989-98.
77. Kim, J.; Peraire, C.; Sola, J.; Johanning, K.M.; Dalton, J.T.; Veverka, K.A. Drug interaction potential of toremifene and Ndesmethyltoremifene with multiple cytochrome P450 isoforms. Xenobiotica, 2011, 41(10), 851-62.